Fundraising Fox

Damora Therapeutics

NASDAQ: DMRA

Copenhagen, US · 3 known investors

Advancing potentially best-in-class therapeutics for myeloproliferative neoplasms.

Biotech

Founders & leadership

CC
Christopher CainNamed on SEC filing
GW
Garrett WinslowNamed on SEC filing
CG
Carl GoldfischerNamed on SEC filing
LF
Lori FirmaniNamed on SEC filing
PH
Peter HarwinNamed on SEC filing
AM
Amit MunshiNamed on SEC filing
HT
Hans T. SchambyeNamed on SEC filing
JD
Jayson DallasNamed on SEC filing
JB
Julianne BrunoNamed on SEC filing

Investors · 3

Access BiotechnologyNew York City
Bay City CapitalreportedSan Rafael · $5M – $10Mvia Carl Goldfischer · board
EIR VenturesreportedStockholmvia Stephan Christgau · board

Reported raises · per SEC filings

Form D private placements
▶$285MraisedNov 2025 · 48 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher CainDirector
  • Garrett WinslowExecutive Officer
  • Carl GoldfischerDirector
  • Lori FirmaniExecutive Officer
  • Peter HarwinDirector
  • Amit MunshiDirector
  • Hans T. SchambyeExecutive Officer, Director
  • Jayson DallasDirector
  • Julianne BrunoDirector
Offering amount
$285M
Amount sold
$285M
Finders' fees
$17.1M
Placement agents
UBS Securities LLC, Leerink Partners LLC, LifeSci Capital, LLC, Jefferies LLC
First sale
Nov 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$64.2MraisedNov 2020 · 42 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jon FreveExecutive Officer
  • Karen WagnerDirector
  • Chandra LeoDirector
  • Soren MollerDirector
  • Soren LemoniusDirector
  • Stephan ChristgauDirector
  • David ShapiroDirector
  • Chao Q. KhuongDirector
  • Carl GoldfischerDirector
  • Amit MunshiDirector
  • Hans SchambyeExecutive Officer, Director
  • Erez ChimovitsDirector
Offering amount
$64.2M
Amount sold
$64.2M
First sale
Sep 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$79.1MraisedJan 2020 · 35 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jakob Dynnes HansenExecutive Officer
  • Hans SchambyeExecutive Officer
Offering amount
$123.7M
Amount sold
$79.1M
First sale
Dec 2019
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Damora Therapeutics do?
Advancing potentially best-in-class therapeutics for myeloproliferative neoplasms.
Who are Damora Therapeutics's investors?
Damora Therapeutics's investors include Access Biotechnology, Bay City Capital, EIR Ventures.
Where is Damora Therapeutics headquartered?
Damora Therapeutics is headquartered in Copenhagen, US.